NVDA
NVIDIA
-- 137.175 TSLA
Tesla
-- 408.117 RGTI
Rigetti Computing
-- 7.5971 AMD
Advanced Micro Devices
-- 128.170 PLTR
Palantir
-- 72.080 
NEWS
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics presented additional Phase 1 results for divesiran in polycythemia vera (PV) patients at the ASH Annual Meeting. The SANRECO study data showed substantial reduction in phlebotomy frequency and lower hematocrit levels in 19 PV patients. Following treatment, only five phlebotomies were required during the 18-week treatment period, compared to 79 phlebotomies before enrollment.
The company also announced dosing of the first subject in the Phase 2 portion of the SANRECO study. Divesiran demonstrated sustained hematocrit reduction, favorable effects on iron metabolism, and consistent target engagement through increased hepcidin levels. The treatment has been well-tolerated with no dose-limiting toxicities.
The company also announced dosing of the first subject in the Phase 2 portion of the SANRECO study. Divesiran demonstrated sustained hematocrit reduction, favorable effects on iron metabolism, and consistent target engagement through increased hepcidin levels. The treatment has been well-tolerated with no dose-limiting toxicities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment